Drug Profile
Research programme: solid tumour therapeutics - NanoSmart
Alternative Names: Autoimmune antinuclear antibodies - Nanosmart; Ewing's sarcoma therapeutics - NanoSmart/Children's Hospital Los Angeles; Human derived antinuclear antibodies - Nanosmart; Tumour necrosis targeted antibodies - NanoSmartLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NanoSmart Pharmaceuticals
- Developer Childrens Hospital Los Angeles; NanoSmart Pharmaceuticals
- Class Antibodies; Immunoconjugates
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ewing's sarcoma; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Ewing's Sarcoma in USA
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA
- 30 Jul 2015 NanoSmart's dactinomycin based drug formulation receives Orphan Drug status for Ewing's Sarcoma in USA